v3.26.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Operating Expenses by Function

The following table provides information about the Company’s operating expenses by function and includes a reconciliation to net loss.

 

 

Three Months Ended March 31,

 

 

 

2026

 

 

2025

 

Revenue

 

 

 

 

 

 

Collaboration revenue

 

$

225

 

 

$

 

Operating expenses:

 

 

 

 

 

 

Research and development

 

 

 

 

 

 

Clinical

 

 

5,376

 

 

 

5,947

 

Manufacturing (pre-commercial)

 

 

3,465

 

 

 

5,447

 

Research

 

 

2,958

 

 

 

5,919

 

Other

 

 

3,044

 

 

 

3,763

 

Total research and development

 

 

14,843

 

 

 

21,076

 

General and administrative

 

 

5,447

 

 

 

6,462

 

Total operating expenses

 

 

20,290

 

 

 

27,538

 

Loss from operations

 

 

(20,065

)

 

 

(27,538

)

Other income, net:

 

 

 

 

 

 

Interest income

 

 

793

 

 

 

635

 

Other income, net

 

 

 

 

 

39

 

Total other income, net

 

 

793

 

 

 

674

 

Net loss before income tax expense

 

 

(19,272

)

 

 

(26,864

)

Income tax expense

 

 

 

 

 

 

Net loss

 

$

(19,272

)

 

$

(26,864

)